Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose-Escalation and Safety Trial of YN968D1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by LSK BioPartners Inc..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Bukwang Pharmaceutical, Co., Ltd.
Information provided by (Responsible Party):
LSK BioPartners Inc.
ClinicalTrials.gov Identifier:
NCT01497704
First received: December 18, 2011
Last updated: October 31, 2012
Last verified: October 2012
  Purpose

This protocol will be divided into two parts: Part 1 will evaluate the safety and pharmacokinetics of three doses of YN968D1 after a single administration followed by a 28-Day continuous course of therapy; Part 2 will evaluate the safety and preliminary efficacy in an open-label administration of YN968D1 at the MTD or a maximum of 750 mg. All subjects in Part 1 and Part 2 of this study will be permitted to continue therapy with only safety monitoring and bimonthly assessments for progression, if the product is well tolerated and the subject has stable disease or better. Up to 72 subjects will be enrolled in this clinical trial.


Condition Intervention Phase
Cancer Patients With Solid Tumors
Drug: YN968D1
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors

Resource links provided by NLM:


Further study details as provided by LSK BioPartners Inc.:

Primary Outcome Measures:
  • Safety in the first 28-Days of Therapy [ Time Frame: 28-Days after Discontinuation of YN968D1 ] [ Designated as safety issue: Yes ]
    The primary endpoint is evaluation of safety during the first 28-day cycle of therapy following the initiation of multiple dosing of YN968D1. The safety variables to be evaluated in this study are adverse events, physical examinations, vital signs (specifically including blood pressure), clinical laboratory evaluations including serum chemistry, hematology (including RBC morphology and reticulocyte count), and urinalysis (with detailed sediment analysis, proteinuria, and 24-hour urine for collection for creatinine clearance and protein), and electrocardiograms (ECGs) in triplicate.


Secondary Outcome Measures:
  • Pharmacokinetic Assessments for AUC, Cmax and Tmax [ Time Frame: Day 1 Single Dose and Day 28 Steady State ] [ Designated as safety issue: No ]
    In Part 1 of this study, full PK profiles of YN968D1 will be obtained following administration of a single oral dose of YN968D1 on Day 1, and at steady state on Day 35±2. In Part 2 of this study, PK sampling will include a pre-dose and at the 4±1 hour time point on the first day of dosing in the first 28-Day cycle of therapy, and pre-dose on days 2, 7, 14 and 28 of the first 28-Day cycle of therapy

  • Tumor Biomarkers for Specific Tumor Types [ Time Frame: Every 28-Days ] [ Designated as safety issue: No ]
    The primary Pharmacodynamic endpoints will include specific serum tumor markers for the target cancer, levels of endothelial growth factor (VEGF), and detection of EC-derived molecules such as sVEGFR-1, sVEGFR-2, sVEGFR-3, sTie-2 and VCAM-1, as well as PIGF. These biomarkers will be measured at baseline and at the end of every two 28-Day cycles of therapy. For patients that continue on repeat 28-Day cycles after the primary evaluation period, biomarkerts will be assessed after each two 28-Day cycles of therapy.

  • Objective Response Rate (RESIST) [ Time Frame: Every 56-Days ] [ Designated as safety issue: No ]
    Anti-tumoral efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) at baseline (Day -14 to -1) and at the end of two 28-Day cycles of therapy (Part 1 - Day 35±2; or Part 2 56±2 Days). For patients that continue on repeat 28-Day cycles after the primary evaluation period, progression will be assessed after each two 28-Day cycles of therapy.


Estimated Enrollment: 42
Study Start Date: April 2012
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: YN968D1
Active therapy arm for safety evaluation
Drug: YN968D1
Daily dosing of YN968D1 for treatment of solid tumors
Other Name: Apatinib

Detailed Description:

Part 1 will include a sequential evaluation of 3 subjects per cohort; cohort 1 at a dose of 100 mg YN968D1, followed by a cohorts 2, 3 and 4 at doses of 250 mg, 500 mg and 750 mg respectively. Initially, each subject will receive one dose of YN968D1 followed by a 7-Day observation period, during which single dose PK assessments and safety monitoring will be performed. If the initial dose is well tolerated, the subject will return on Day 8 and receive 28-Days of continuous YN968D1 oral administration daily. Each subject will subsequently be assessed for safety and disease progression on Day 35±2 and steady state pharmacokinetic sampling will be obtained. Patients may continue on therapy for an additional 28-Day cycles without dose interruption if the therapy is well tolerated. Efficacy assessments (biomarkers) and disease progression (RECIST imaging) will be assessed every two 28-Day cycles. The subjects will be assessed for safety for at least 28-Days after the last dose of YN968D1.

For Part 1 of this study, a Dose Limiting Toxicity (DLT) event is defined as any of the following events that are assessed by the Investigator as probably or possibly related to YN968D1 and occur during or after the initial dose on Day 1 through Day 35 of the first cycle of therapy.

  • CTCAE Grade 4 event
  • Grade 3 febrile neutropenia (<1,000 neutrophils/mL)
  • Grade 3 hematologic toxicity with duration > 7 days
  • Grade 3 non-hematologic toxicity (except for nausea, vomiting, diarrhea that continues despite optimal medical management)

If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If two (2) DLTs are experienced in any cohort, the study will be paused until the safety events are evaluated and discussed with the FDA to determine if the trial may continue.

Part 2 of this study will include up to 30 subjects. Each subject will receive a 750 mg dose or the maximum tolerated dose of YN968D1 from part 1 of the study for continuous 28-Day cycles of therapy. If a subject experiences an intolerable side effect a dose reduction or a dose interruption for up to 7-Days is allowed at the discretion of the investigator. Subjects will be evaluated for RECIST (version 1.1) response at the end of the second cycle of therapy on Day 56±3 of the Part 2 study. Safety reporting will be continued for 28-Days from the last dose of study medication.

All subjects in Part 1 and 2 of this trial will be eligible to continue therapy provided they have a least stable disease or better and are, in the opinion of the investigator, adequately tolerating treatment with YN968D1.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 years of age or older
  2. Subjects may be enrolled with the following malignancies:

    • Part 1: Subjects with any solid malignant tumor that are refractory to conventional therapy or the subject does not tolerate the conventional therapy
    • Part 2: Subjects diagnosed with NSCLC, CRC, RCC, Gastric cancer, GIST or triple negative Breast Cancer that are refractory to conventional therapy or the subject does not tolerate the conventional therapy
  3. Evaluable disease defined by RECIST 1.1 as measured by a suitable imaging technique
  4. Life expectancy ≥ 3 months
  5. Subject must be suitable for oral administration of study medication
  6. Signed written informed consent
  7. Adequate bone marrow, renal, and liver function as manifested by the following:

    • CBC: ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9.0 g/dL
    • CMP: Creatinine clearance > 50 mL/min or serum creatinine < 1.5 x ULN, serum bilirubin < 2.5 x ULN, AST and ALT ≤ 5.0 × ULN
    • Coagulation profile with PT and INR, each ≤ 1.5 x ULN
    • Proteinuria < 200 mg by 24- hour urine collection without evidence of active sediment or hematuria
  8. ECOG performance status ≤ 2
  9. Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of YN968D1 until 4 weeks after discontinuing study drug and male subjects must agree to use contraceptive measures during the study and ending 4 weeks after last dose of study drug
  10. Female patients of child-bearing potential are confirmed to have either a negative serum ß-hCG test, or have been evaluated by a gynecologist to confirm the patient is not pregnant, within 7 days prior to administration of initial dose of YN968D1
  11. Ability and willingness to comply with the study protocol for the duration of the study and with follow-up procedures

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Therapy with clinically significant systemic anticoagulant or antithrombotic agents within 7 days prior to first scheduled dose of YN968D1 that may prevent clotting and in the opinion of the investigator would place the subject at risk.
  3. Hemoptysis within 3 months prior to first scheduled dose of YN968D1
  4. Cytotoxic chemotherapy, immunotherapy, or radiotherapy within 4 weeks (6 weeks in cases of mitomycin C, nitrosourea, lomustine) prior to first scheduled dose of YN968D1
  5. Surgery or visceral (e.g., hepatic or renal) biopsy within 28 days prior to first scheduled dose of YN968D1
  6. Minor surgical procedure performed within 7 days prior to first scheduled dose of YN968D1
  7. Prior exposure to YN968D1 (prior treatment with an angiogenesis inhibitor is not exclusionary)
  8. Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19.
  9. Known history of human immunodeficiency virus infection (HIV)
  10. Subjects with active bacterial infections and/or receiving systemic antibiotics
  11. Current or past diagnosis of leukemia within the past 5 years
  12. Prior radiotherapy at the target lesion
  13. Known CNS metastases or clinical evidence of CNS involvement that is not stable for last 3 months by radiology documentation
  14. Medical history of non-healing wound within past 2 weeks
  15. History of bleeding diathesis or bleeding within 14 days prior to enrollment
  16. Medical history of clinically significant thrombosis (bleeding or clotting disorder) within the past 3-months that in the opinion of the investigator may place the patient at risk of side effects on an anti-angiogenesis product
  17. History of non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months that in the opinion of the investigator may place the patient at risk of side effects on an anti-angiogenesis product
  18. History of idiopathic or hereditary angioedema
  19. History of sickle cell or any hemolytic anemia
  20. History of uncontrolled hypertension that in the opinion of the investigator is not well managed by medication and may place the patient at risk when taking a VEGF inhibitor
  21. Complete left bundle branch block (LBBB), bifascicular block (RBBB with either left anterior hemiblock or left posterior hemiblock)
  22. Any clinically significant ST segment and/or T-wave abnormalities
  23. Presence of unstable atrial fibrillation (ventricular response rate > 100 bpm). Patients with stable atrial fibrillation are allowed in the study provided they do not meet another exclusion criteria
  24. Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication
  25. Congestive heart failure (New York Heart Association class III-IV)
  26. History of other significant cardiovascular disease or vesicular disease within the last 6 months (e.g. such as hypertensive crisis, hypertensive encephalopathy, stroke or TIA, or significant peripheral vascular disease) that in the opinion of the investigator may place the patient at risk when taking a VEGF inhibitor
  27. History of significant gastrointestinal disorders that in the opinion of the investigator may place the patient at risk when taking a VEGF inhibitor; such as an abdominal fistula, GI perforation, or bleeding ulcer within 2 months of treatment
  28. QTcF >450 msec on screening ECG
  29. Baseline echocardiogram (within 2 months) with left ventricular ejection fraction (LVEF) <50%
  30. History of clinically significant glomerulonephritis, biopsy proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies
  31. History of myocardial infarction within the past 6 months
  32. Treatment with an investigational agent within the longest time frame of either 5 half-lives or 30 days of initiating study drug
  33. Medical or psychiatric illness that, in the opinion of the Investigator, may impact the safety of the subject or objectives of the study
  34. Known recreational substance use or psychiatric illness that, in the opinion of the Investigator, may affect compliance with scheduled visits
  35. Known hypersensitivity to YN968D1 or components of the formulation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01497704

Locations
United States, Utah
Huntsman Cancer Institute Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Sunil Sharma, MD, FACP    801-587-5597    sunil.sharma@hci.utah.edu   
Contact: Teri Wyum, RN    801-587-5559    teri.wyum@hci.utah.edu   
Principal Investigator: Sunil Sharma, MD, FACP         
Korea, Republic of
ASAN Medical Center Active, not recruiting
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
LSK BioPartners Inc.
Bukwang Pharmaceutical, Co., Ltd.
Investigators
Principal Investigator: Sunil Sharma, MD, FACP Huntsman Cancer Institute
Principal Investigator: Yoon-Koo Kang, MD, PhD Asan Medical Center
  More Information

No publications provided

Responsible Party: LSK BioPartners Inc.
ClinicalTrials.gov Identifier: NCT01497704     History of Changes
Other Study ID Numbers: BK-LSK-AM101
Study First Received: December 18, 2011
Last Updated: October 31, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by LSK BioPartners Inc.:
Cancer
Tumor
Oncology
Antiangiogenesis

ClinicalTrials.gov processed this record on November 23, 2014